肾移植中的补体激活
本文综述补体系统在肾移植中的作用,涉及缺血再灌注损伤、同种异体排斥反应及异种移植排斥,并汇总补体靶向生物制剂的临床使用进展。文中指出补体靶向策略仍处早期阶段,但新药发现有望改进现有疗法。
要点
- 补体激活参与移植肾缺血再灌注损伤和排斥反应。
- 补体失调相关肾病移植后复发率高,需关注补体状态。
- 补体靶向治疗尚处早期,新药发现推动方案优化。
核心结论
- 补体靶向策略在肾移植中仍处于早期阶段,但新药发现鼓励重新设计现有疗法并开发更有效治疗。
研究设计与样本
- 综述,汇总补体系统在肾移植中作用及补体靶向治疗临床进展的现有知识。
主要发现
- 补体激活强烈参与缺血再灌注介导的损伤及同种异体移植物和异种移植物的排斥。
- 与补体系统失调相关的肾脏疾病在移植后复发率高。
临床怎么用
- 移植前后需精确理解补体激活级联,以制定靶向补体的成功策略。
局限性
- 补体靶向策略的当前研究结果仍处于早期阶段,相关方法存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term graft survival remains a challenge in kidney transplantation and, due to scarcity of available organs, solutions such as xenotransplantation have been revived, and testing of new agents, including complement-targeting biologicals with potential to improve transplant outcomes, has been enhanced. The complement system plays a critical role in the reaction of the host's immune system to the transplanted foreign kidney. Activation of the complement system is strongly involved in ischemia/reperfusion-mediated injury and rejection of allografts as well as xenografts, and post-transplant recurrence rates are high in kidney diseases linked to complement system dysregulation. Therefore, the precise understanding of the complement activation cascade is important for the development of successful strategies that target complement before and after transplantation. This article compiles the current knowledge on the role of the complement system in kidney transplantation, examines recent developments in the clinical use of complement-targeting therapeutics and discusses the limitations of these approaches. While the current study results indicate that complement-targeting strategies are still in their early stages, promising findings related to the discovery of new agents encourage the redesign of existing therapeutic approaches and the development of more effective treatments.
引用
- Kanbay M, Ozbek L, Guldan M, et al. Complement activation in kidney transplantation. Nephrol Dial Transplant. 2026. PMID: 41042248. doi:10.1093/ndt/gfaf206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。